Here’s a plan to get India 10-20% extra COVISHIELD vaccines doses overnight!

How could this be possible? Read on to find out.

🧵 1/

Antibody Responses After a Single Dose of ChAdOx1 nCoV-19 Vaccine in HCWs Previously Infected with SARS-CoV-2 medrxiv.org/content/10.110…
A study found that HCWs who had recovered from COVID-19 up-to 11 months prior responded incredibly to a single dose of AstraZeneca vaccine (COVISHIELD).
They had neutralizing antibodies against wild type virus but also neutralized P.1 & B.1.351 (immune escape variants)!
2/
In fact those who had COVID-19 in the past and took a single dose of AZ (COVISHIELD) had higher neutralizing antibodies than those who took 2 doses of Pfizer mRNA vaccine! That’s right - past infection plus 1 dose AZ higher nAbs than 2 doses of Pfizer!
3/

medrxiv.org/content/10.110…
A single dose of COVISHIELD in those who had COVID-19 upto 11 months prior produces an amazing response. They can neutralize even the most concerning immune escape variant B.1.351 (variant identified by South African researchers)! Response is better than 2 doses of Pfizer.
4/
A single dose of AZ (COVISHIELD) after natural infection upto 11 months prior has higher nAbs than 2 doses of Pfizer. We know 2 doses of Pfizer produce higher nAbs than 2 doses of COVISHIELD.
Change guidelines! Give those with past COVID-19 just 1 dose of COVISHIELD.
5/
We always have to weight the benefit of any vaccine against the risk. Those who have had COVID-19 are fully protected after 1 dose of COVISHIELD. Why would we give them another dose? What value dose it provide them? There’s the rare risk of dangerous clots (VITT).
6/
In these individuals the second dose doesn’t add much benefit (they already have a better response than 2 doses of Pfizer). So why should they take any risk? Even a negligible risk is unacceptable when there isn’t tangible benefit! So from their pint of view 1 dose makes sense
7/
We have a catastrophic vaccine shortage in our country.
30-40% of people have likely had past infection. If we give them just a single dose of COVISHIELD we save 15-20% vaccine doses! Every dose saved is 1 extra dose we desperately need!
8/
So from the individual point of view 1 dose makes more sense. From the public health point of view 1 dose makes sense.
From the govt. point of view 1 dose makes sense as cost to state is reduced.
We need these extra doses so badly. 15-20% more doses overnight!
9/
How to know who was infected in past? Antibody tests!
Won’t that be too cumbersome? Use rapid tests just before vaccination!
What about false negative?
Irrelevant - someone gets an extra 2nd dose.
What about false positive? Orthogonal confirmation with a 2nd rapid test!
10/
We can use rapid tests for anti-RBD antibodies prior to first dose. That way no one gets sent back without 1 dose.
Here’s a thread to explain the plan in detail:
11/
I want to clarify a COI
I consulted on R&D for a company that developed a rapid anti-RBD test. I DO NOT earn any royalties and WOULD NOT finically benefit from sales of this test. I explained this plan to the company months back, they understood the importance of such a test
12/
Adding @sailorrooscout 🧵

Also want to point out this is a pre-print. It has not been peer reviewed. The sample size is small. BUT we are in a moment of national crisis. We need to be bold in our response. We can implement pre dose 1 testing and measure response post dose 1
13/
If plan doesn’t work at worst we added some pre-dose 1 rapid antibody tests. We would know based on the post dose 1 serology if the plan was working or not. If it doesn’t work we can always give the 2nd dose. If it’s works we get an extra 15-20% COVISHIELD doses. No downside!
14/

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Dr. Swapneil Parikh

Dr. Swapneil Parikh Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @swapneilparikh

13 May
Provided COVAXIN single dose efficacy is >70%, models support delaying COVAXIN 2nd dose except for 65 years +
We should have had quality Ph3 data and real world data on COVAXIN by now. Unbelievable that we’re still doing guess work.
🧵
1/
Modeling study helps us understand lives saved with delayed second dose of Covaxin.

Assuming vaccination rate of 0.3% of population / day. The total cumulative mortality on day 180 is seen to be lower as below depending on efficacy. Makes sense if efficacy >70%
2/ Image
Delayed second dose except for 65+ allows us to save lives but reduces the risk due to uncertain efficacy. Bottom line if COVAXIN single dose efficacy is >70% this approach makes sense given India’s daily vaccination rate. We’re unlikely to ever hit 1% population / day
3/ Image
Read 9 tweets
30 Jan
If we have to wait till June for COVOVAX, Indian regulators should hang their heads in shame.
They gave COVAXIN an EUA without any efficacy data or Ph3. Novavax has efficacy data from Ph3 in U.K. and Ph2 in SA. Ph3 in USA and Mexico underway. 1/
Indian regulators literally rewrote the rules for COVAXIN citing hypothetical superior efficacy against variants. What a load of BS (BOGUS science). They made up the restricted EUA in clinical trial mode BS. But a vaccine with 85%+ efficacy in Ph3 against B.1.1.7 is too risky! 2/
Is COVISHIELD good? Yes. But there’s a lack of data for >55 years. That’s more an issue with the trial than the vaccine. Is COVAXIN good? I don’t know, no publicly available Ph3 data. COVOVAX has AMAZING immunogenicity & reported AMAZING efficacy (need 2 wait for the preprint) 3/
Read 4 tweets
29 Jan
Let me just try to preempt all the BS (bad science) we will hear about hypothetical superiority of COVAXIN against variants vs Novavax. A thread 🧵 1/
Novavax is proven efficacious against OG COVID-19 and B.1.1.7 in a Phase 3 clinical trial in U.K. We should soon have the data in a preprint / peer reviewed publication. The confidence in the results will increase as more cases occur. 2/
Novavax has a Phase 2 trial in South Africa with an efficacy endpoint. That trial reported efficacy albeit reduced against B.1.351. The number of participants in the study was small, number of cases were low and therefore confidence in these results in lower than we need. 3/
Read 14 tweets
30 Jul 20
Mumbai’s sero-prevelance study - detailed report with technical details : tcs.tifr.res.in/~sandeepj/avai… @CT_Bergstrom @mlipsitch @cmyeaton @nataliexdean @apoorva_nyc @velumania 1/
2/Study period: 14 days in July 20.
Areas selected:Three wards (R-North, M-West and F-North) in Mumbai were chosen based on: (a) City and Suburban areas (b) East, West and North areas and (c) representative of areas with low to high prevalence based on reported cases on 02/06/20
3/Sampling design: Sampling from households in impoverished tenements or buildings, which were separated by at least 3 households/buildings ensured geographically separate and a systematic method for non-overlapping area coverage.
Read 14 tweets
17 Jun 20
Those of us following #RECOVERYtrial know it’s one of the most important clinical trials for COVID-19, not just for its potential to identify new therapeutic options but also to temper the excitement over unproven therapies. 1/
My thoughts on the RECOVERY trial PRESS release on mortality benefit for COVID-19 with dexamethasone.
RECOVERY trial is a large randomized controlled trial with multiple arms. 11k+ patients and multiple treatments being evaluated. See image for therapeutics under evaluation. 2/
First, what is dexamethasone?
Dexamethasone is a corticosteroid, commonly called a steroid (not the anabolic kind). In addition to many other effects, it can reduce the inflammatory resonse caused by an out of control immune system. 3/
Read 16 tweets
13 Jun 20
@ShamikaRavi We explored the possible effect of the monsoons on transmission SARS-CoV-2 in #TheCoronavirusBook. Influenza does activity does spike in the monsoon and post monsoon period in tropical countries. 1/
@ShamikaRavi Possible reasons: clustering of people indoors with increased social contact, high RH + precipitation and decreased solar radiation can prolong viron stability, lower vitamin D levels may play a role. 2/
@ShamikaRavi Let’s look at how influenza’s transmission changes with weather. First let’s distinguish between transmission patterns in temperate countries and tropical countries.
3/
Read 17 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(